aid: clasp-therapeutics
name: Clasp Therapeutics
description: 'Clasp Therapeutics, Inc. is a clinical-stage precision immuno-oncology
  company developing next-generation T cell engagers (TCEs) built on its proprietary
  pHLAre platform, which redirects T cells to mutant peptides — such as p53 R175H and
  mutant KRAS — presented by specific HLA molecules on the surface of tumor cells.
  The approach is intended to yield off-the-shelf, antibody-like medicines that hit
  common oncogenic driver mutations with tumor-exclusive specificity. Its lead
  candidate CLSP-1025 (p53 R175H / HLA-A*02:01) is in the Phase 1 GUARDIAN-101 trial
  (NCT06778863), and CLSP-5282, a first-in-class KRas-directed TCE, was unveiled at
  AACR 2026. Founded on research from Bert Vogelstein, Drew Pardoll and colleagues at
  Johns Hopkins, the company launched in March 2024 with $150 million led by Catalio
  Capital Management, Third Rock Ventures and Novo Holdings, and operates from
  Cambridge, Massachusetts and Rockville, Maryland. Clasp Therapeutics is a
  therapeutics developer and publishes no public API, developer program, SDK, or
  machine-readable specification.'
url: https://raw.githubusercontent.com/api-evangelist/clasp-therapeutics/refs/heads/main/apis.yml
image: http://static1.squarespace.com/static/65d6268f8ea1f7001e49412c/t/65dea444ac80a07c1b522dbc/1709089860325/Clasp-logo-white-RGB.png?format=1500w
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-09'
modified: '2026-08-09'
tags:
- Company
- Biotechnology
- Immuno-Oncology
- Oncology
- Therapeutics
- T Cell Engagers
- Precision Medicine
- Clinical Stage
- Life Sciences
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/clasp-therapeutics-domain-security.yml
- type: LLMsTxt
  url: llms/clasp-therapeutics-llms.txt
- type: Website
  url: https://www.clasptx.com/
- type: Blog
  url: https://www.clasptx.com/press-release-publications
- type: BlogRSS
  url: https://www.clasptx.com/press-release-publications?format=rss
- type: PrivacyPolicy
  url: https://www.clasptx.com/privacy-policy
- type: LinkedIn
  url: https://www.linkedin.com/company/clasp-therapeutics/
- type: SecondaryMarketListing
  url: https://www.hiive.com/securities/clasp-therapeutics-stock
x-enrichment:
  date: '2026-08-09'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Clasp Therapeutics is a clinical-stage biotech whose product is a T cell engager
    drug candidate in a Phase 1 trial; its 41-URL Squarespace sitemap contains only leadership,
    founders, board, press-release and privacy-policy pages, and no api./developer./docs.
    subdomain resolves in DNS.
  evidence:
  - url: https://www.clasptx.com/sitemap.xml
    status: 200
  - url: https://www.clasptx.com/openapi.json
    status: 404
  - url: https://www.clasptx.com/developers
    status: 404
  - url: https://www.clasptx.com/graphql
    status: 404
  - url: https://www.clasptx.com/llms.txt
    status: 404
  - url: https://www.clasptx.com/.well-known/agent-card.json
    status: 404
  - url: https://www.clasptx.com/.well-known/security.txt
    status: 404
  checked: '2026-08-09'